China has relaxed its rules for the sale of asset-backed securities (ABS), making it easier for banks to transform some of the nation’s 85 trillion yuan (US$13.71 trillion) of outstanding loans into tradable notes.
Institutions no longer need to seek approval from regulators for each ABS sale, the People’s Bank of China said yesterday on its Web site.
Those licensed to sell ABS’ by the China Banking Regulatory Commission are to be able to determine the timing and location of the issuances after registering the amount of planned sales and their maturities with the commission, according to the new rules.
The new rules covering ABS sales on the and exchange-traded and interbank markets allow issuers to decide themselves how often they conduct sales and what the quotas would be.
Asset-backed securitization, in which lenders package loans into collateral for note sales, can help banks make room on their balance sheets for new lending.
“It will cause an explosive growth of China’s ABS market,” Australia and New Zealand Banking Group Ltd Shanghai-based economist Zhou Hao (周浩) said of the new rules.
“It’s a very positive move for the banking system and the economy,” Zhou said.
Chinese banks sold a total of 269.1 billion yuan of securities backed by loans last year, compared with 15.8 billion yuan in 2013, according to data compiled by Bloomberg.
Issuances have been 33.1 billion yuan this year.
Sales might increase to between 1 trillion and 2 trillion yuan per year as a result of the rule change, Zhou said.
The rule change coincides with Premier Li Keqiang’s (李克強) pledge last month to “make better use of existing funds” to support economic growth, which moderated last year to the slowest pace since 1990.
The expansion of China’s ABS market also comes as the securities have attracted global regulatory scrutiny since the 2008 financial crisis, when loans to subprime home buyers in the US went bad.
China resumed approvals of ABS issuances in 2012 after having suspended an earlier trial in 2008.
“It’s far too early to worry about any US-style ABS risks in China,” Zhou said.
Just a few years ago, the millennial generation — generally defined as those born from the early 1980s through the mid-1990s — was synonymous with youthful rebellion. However, now, as the millennials ease into early middle age, they are finding their path out of their parents’ basement to be a lot harder than it was for earlier generations. The fundamental problem is that millennials are not building wealth. The wealth of the median US household headed by someone 35 or younger has actually shrunk in inflation-adjusted terms since the mid-2000s, even as the wealth of older Americans has continued to grow. An
‘LITTLE CHOICE’: The airline said it expected only about 8,000 of its 29,000 employees to be working by next month, but hoped to have 21,000 in the next two years Qantas Airways Ltd plans to cut at least 6,000 jobs and keep 15,000 more workers on extended furloughs as Australia’s largest airline tries to survive the coronavirus pandemic. Qantas yesterday announced a plan to reduce costs by billions of dollars and raise fresh capital. The plan includes grounding 100 planes for a year or more and immediately retiring its six remaining Boeing Co 747 planes. Chief executive Alan Joyce said the airline has to become smaller as it braces for several years of much lower revenues. He said the furloughed workers faced a long interruption to their airline careers. “The actions that we’re taking
Apple Inc’s decision to stop using Intel Corp processors in its Mac computers and switching to its own chips might benefit Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) and boost Taiwan’s high-tech exports, Australia and New Zealand Banking Group (ANZ) said in a note on Tuesday. The US tech giant announced the “Apple silicon” initiative at its annual Worldwide Developers’ Conference, which started on Monday. The company said the first Mac powered by its own chips would debut by the end of this year and all product lines might shift to the new architecture in the next two years. TSMC is likely to
EXPERIMENTAL DRUG: While news about a COVID-19 vaccine is more eye-catching, developing a treatment would be more viable, the Senhwa boss said Senhwa Biosciences Inc (生華科) aims to raise NT$1.5 billion (US$50.57 million) by issuing 15 million new common shares in the third quarter of this year to fund the research of new drugs, including the experimental drug Silmitasertib for the treatment of COVID-19, the company said on Monday. That would be the firm’s largest fundraising effort after it raised more than NT$1.4 billion from an initial public offering on the Taipei Exchange (TPEX) in April 2017, chief financial officer Sarah Chang (張小萍) told the Taipei Times by telephone. The price of the new shares would depend on the firm’s average share price